Pramiconazole, a triazole compound for the treatment of fungal infections

IDrugs

Volumn 11, Issue 9, 2008, Pages 661-670

  Geria, A N ^a   Scheinfeld, N S ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOLINE; ERGOSTEROL; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; ATRIOVENTRICULAR BLOCK; CANDIDA ALBICANS; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONSTIPATION; DERMATOMYCOSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; FUNGAL CELL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHIDROSIS; LIVER INJURY; LIVER TOXICITY; MALASSEZIA; MALASSEZIA GLOBOSA; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NECK PAIN; NONHUMAN; ONYCHOMYCOSIS; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; SEBORRHEIC DERMATITIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; VITAL SIGN; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLES; MYCOSES; PATENTS AS TOPIC; TRIAZOLES;

EID: 51049107726     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 334443 Mechanisms of resistance to azole antifungal compounds. Marichal P CURR OPIN ANTI-INFECTIVE INVEST DRUGS 1999 1 3 318-333
2. 405646 Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Venkatakrishnan K, von Moltke LL, Greenblatt DJ CLIN PHARMACOKINET 2000 38 2 111-180
3. 588942 The novel azole R-126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp and Microsporum canis. Bossche HV, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, Meerpoel L, Odds F, Borgers M ANTIMICROB AGENTS CHEMOTHER 2004 48 9 3272-3278
4. 50 values that were 3- to 8-fold lower than with itraconazole.
5. 588979 Form S-1/A - Barrier Therapeutics Inc. Barrier Therapeutics Inc FORM S-1 2004 March 15
6. 622113 Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. Meerpoel L, Backx LJ, Van der Veken LJ, Heeres J, Corens D, De Groot A, Odds FC, Van Gerven F, Woestenborghs FA, Van Breda A J MED CHEM 2005 48 6 2184-2193
7. 657938 Activity of the triazole antifungal R-126638 as assessed by corneofungimetry. Pierard-Franchimont C, Ausma J, Wouters L, Vroome V, Vandeplassche L, Borgers M, Cauwenbergh G, Pierard GE SKIN PHARMACOL PHYSIOL 2006 19 1 50-56 • This article describes a study assessing levels of pramiconazole in epidermal stratum corneum using corneofungimetry. Informative data were obtained regarding the persistence of pramiconazole in the skin despite the cessation of treatment.
8. 762420 NexMed announces patient dosing in phase 3 program for anti-fungal product. NexMed Inc PRESS RELEASE 2007 February 01
9. 783614 A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Pierard GE, Ausma J, Henry F, Vroome V, Wouters L, Borgers M, Cauwenbergh G, Pierard-Franchimont C DERMATOLOGY 2007 214 2 162-169
10. 814103 The efficacy of oral treatment with pramiconazole in pityriasis versicolor: A phase IIa trial. Faergemann J, Ausma J, Vandeplassche L, Borgers M BR J DERMATOL 2007 156 6 1385-1388
11. 834241 Barrier's phase III Hyphanox trial for onychomycosis fully enrolled. Barrier Therapeutics Inc PRESS RELEASE 2007 September 28
12. 841003 Barrier Therapeutics announces promising results from ongoing phase 2a study of pramiconazole in onychomycosis. Barrier Therapeutics Inc PRESS RELEASE 2007 October 19
13. 845028 Form 10K for the year ended 31 December 2006. Barrier Therapeutics Inc FORM 10-K 2007 March 12
14. 878515 Pramiconazole, a novel oral antifungal agent, effectively treats pityriasis versicolor: Results of a dose-finding clinical study. Faergemann J, Borgers M, Barranco C, Spellman M J AM ACAD DERMATOL 2008 58 2 Suppl 2 Abs P1704 •• This article describes the first large-scale, dose-finding clinical trial assessing several regimens of pramiconazole in patients with tinea versicolor. A linear dose-response relationship for treatment effectiveness was observed, and pramiconazole was determined to be generally well tolerated.
15. 880130 Absence of an active metabolite for the triazole antifungal pramiconazole. Ausma J, Pennick G, Bohets H, van de Velde Vera BM, Fothergill A ACTA DERM VENEREOL SUPPL 2007 87 1 22-26
16. 880131 In vitro activity of R-126638 and ketoconazole against Malassezia species. Faergemann J, Ausma J, Borgers M ACTA DERM VENEREOL SUPPL 2006 86 4 312-315
17. 888381 NanoBio Corporation completes interim analysis of phase 2 clinical trial in onychomycosis. NanoBio Corp PRESS RELEASE 2008 March 20
18. 900966 Barrier Therapeutics announces first quarter 2008 financial results. Barrier Therapeutics Inc PRESS RELEASE 2008 April 29
19. 910792 York Pharma plc ('York Pharma' or 'the Company'). York Pharma plc PRESS RELEASE 2008 May 28
20. 916327 The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: Two exploratory phase IIa trials. Decroix J, Ausma J, Cauwenbergh G, Borgers M, Wouters L BR J DERMATOL 2008 158 4 854-856
21. 919320 Stiefel plans $148 million acquisition of Barrier Therapeutics. Stiefel Laboratories Inc PRESS RELEASE 2008 June 23
22. 919911 Schering-Plough - Product pipeline - June 2008. Schering-Plough Corp COMPANY WORLD WIDE WEB SITE 2008 June 10
23. 923522 Efficacy and safety of short-term itraconazole in tinea pedis: A double-blind, randomized, placebo-controlled trial. Svejgaard E, Avnstorp C, Wanscher B, Nilsson J, Heremans A DERMATOLOGY 1998 197 4 368-372
24. 923524 Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. Gupta AK, Doncker PD, Heremans A, Stoffels P, Pierard GE, Decroix J, Heenen M, Degreef H J AM ACAD DERMATOL 1997 36 5 Pt 1 789-792
25. 923532 Itraconazole in the treatment of dermatophytes: A comparison of two daily dosages. Degreef H, Marien K, De Veylder H, Duprez K, Borghys A, Verhoeve L REV INFECT DIS 1987 9 Suppl 1 S104-S108
26. 923533 Itraconazole for the treatment of onychomycosis. Gupta A, De Doncker P, Scher R, Haneke E, Daniel R, Andre J, Baran R INT J DERMATOL 1998 37 4 303-308
27. 923536 A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Garcia-Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH BR J CLIN PHARMACOL 1999 48 6 847-852
28. 923537 Oral treatments for toenail onychomycosis: A systematic review. Crawford F, Young P, Godfrey C, Bell-Syer SE, Hart R, Brunt E, Russell I ARCH DERMATOL 2002 138 6 811-816
29. 923538 The treatment of dermatophytosis: Safety considerations. Smith EB J AM ACAD DERMATOL 2000 43 5 Suppl S113-S119
30. 923539 Treatment of tinea capitis: Beyond griseofulvin. Elewski BE J AM ACAD DERMATOL 1999 40 6 Pt2 S27-S30
31. 923541 Cytochromes P450 in fungi. Vanden Bossche H, Koymans L MYCOSES 1998 41 Suppl 1 32-38
32. 923542 Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Zarn JA, Bruschweiler BJ, Schlatter JR ENVIRON HEALTH PERSPECT 2003 111 3 255-261
33. 923544 Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. Lamb DC, Kelly DE, Baldwin BC, Kelly SL CHEM BIOL INTERACT 2000 125 3 165-175
34. 923546 Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ CLIN PHARMACOL THER 1986 39 6 654-659
35. 923547 Risk of serious skin disorders among users of oral antifungals: A population-based study. Castellsague J, Garcia-Rodriguez LA, Duque A, Perez S BMC DERMATOL 2002 2 14
36. 923746 Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact. Kanafani ZA, Perfect JR CLIN INFECT DIS 2008 46 1 120-128
37. 923749 Skin diseases associated with Malassezia species. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr J AM ACAD DERMATOL 2004 51 5 785-798
38. 923750 Management of seborrheic dermatitis and pityriasis versicolor. Faergemann J AM J CLIN DERMATOL 2000 1 2 75-80
39. 923752 Topical treatment of common superficial tinea infections. Weinstein A, Berman B AM FAM PHYS 2002 65 10 2095-2102
40. 923754 Onychomycosis: Classification and diagnosis. Gupta AK, Ryder JE, Summerbell RC J DRUGS DERMATOL 2004 3 1 51-56
41. 923759 Specific inhibition of fungal sterol biosynthesis by SF-86-327, a new allylamine antimycotic agent. Ryder NS ANTIMICROB AGENTS CHEMOTHER 1985 27 2 252-256
42. 923760 Antifungal activity of Penicillium griseofulvin mycelium. Huddleston WA VET REC 1970 86 3 75-76
43. 923762 Current trends in onychomycosis therapy: A literature review. Hecker D MT SINAI J MED 1997 64 6 399-405
44. 924179 Fungal infections of the skin: Infection process and antimycotic therapy. Borgers M, Degreef H, Cauwenbergh G CURR DRUG TARGETS 2005 6 8 849-862
45. 924226 Cytochrome P450: Target for itraconazole. Vanden Bossche H, Bellens D, Cools W, Gorrens J, Marichal P, Verhoeven H, Willemsens G, De Coster R, Beerens D, Haelterman C, Coene MC et al DRUG DEV RES 1986 8 1-4 287-298
46. 924541 Post-treatment levels of pramiconazole, a new oral antifungal, in nails. Ausma J, Vandeplassche G, Bruynseels J, Grindel M CONGR EUR ACAD DERMATOL VENEREOL 2006 October 4-7 Abs P014.9
47. 924542 Tolerability, safety and pharmacokinetics of the novel antifungal R-126638. Ausma J, Bruynseels J, Snoeck E, Blockhuys S, van Rossem K, Borgers M CONGR EUR ACAD DERMATOL VENEREOL 2004 18 Suppl2 P08.40
48. 926526 Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Back DJ, Tjia JF BR J CLIN PHARMACOL 1991 32 5 624-626
49. 931375 Chapter 48: Antifungal Agents. Bennet JE GOODMAN & GILMANS THE PHARMACOLOGICAL BASIS OF THERAPEUTICS (EDS: BRUNTON LL, LAZO JS, PARKER KL) 2005 McGraw-Hill, New York 11th Edition 1225-1242
50. 931376 Role of antifungal agents in the treatment of seborrheic dermatitis. Gupta AK, Nicol K, Batra R AM J CLIN DERMATOL 2004 5 6 417-422
51. 931381 Prevalence and epidemiology of onychomycosis. Vender RB, Lynde CW, Poulin Y J CUT MED SURG 2006 10 Suppl 2 28-33
52. 931384 Cutaneous infections dermatophytosis, onychomycosis and tinea versicolor. Vander Straten MR, Hossain MA, Ghannoum MA INFECT DIS CLIN N AM 2003 17 1 87-112
53. 931386 Etiology and management of seborrheic dermatitis. Gupta AK, Madzia SE, Batra R DERMATOLOGY 208 2 89-93
54. 932296 Stiefel Laboratories completes acquisition of Barrier Therapeutics. Stiefel Laboratories Inc PRESS RELEASE 2008 August 06